Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GSK | 52.24% | $77.95B | +0.13% | 4.18% |
NVS | 47.62% | $234.94B | +15.95% | 3.27% |
HLN | 47.23% | $46.13B | +21.28% | 1.73% |
BIIB | 46.48% | $19.52B | -40.70% | 0.00% |
PFE | 46.30% | $143.95B | -8.59% | 6.72% |
AZN | 46.12% | $220.60B | -7.38% | 2.19% |
REGN | 45.76% | $59.14B | -46.51% | 0.16% |
JNJ | 43.05% | $374.29B | +6.77% | 3.23% |
SNN | 42.95% | $13.20B | +20.02% | 2.48% |
UL | 42.66% | $150.63B | +11.64% | 3.17% |
TMO | 42.57% | $161.48B | -20.14% | 0.38% |
GMAB | 42.33% | $12.57B | -18.73% | 0.00% |
ALC | 41.67% | $44.17B | +1.33% | 0.38% |
ING | 41.16% | $68.20B | +27.18% | 5.29% |
VOD | 41.08% | $26.11B | +20.70% | 4.54% |
COO | 40.81% | $14.57B | -14.61% | 0.00% |
GILD | 39.83% | $138.71B | +67.46% | 2.80% |
DHR | 39.76% | $144.92B | -15.63% | 0.58% |
MDT | 39.72% | $113.11B | +14.40% | 3.18% |
KHC | 39.71% | $32.03B | -15.67% | 5.93% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RRGB | -13.97% | $122.20M | +4.87% | 0.00% |
MXL | -12.03% | $1.26B | -32.23% | 0.00% |
AMPY | -10.90% | $132.71M | -53.00% | 0.00% |
HUSA | -10.04% | $19.66M | -19.53% | 0.00% |
XGN | -9.36% | $152.37M | +285.08% | 0.00% |
GALT | -8.88% | $137.34M | +0.93% | 0.00% |
ORN | -8.47% | $358.75M | +5.34% | 0.00% |
TGI | -8.00% | $2.00B | +63.68% | 0.00% |
DFDV | -7.68% | $300.56M | +2,130.16% | 0.00% |
FIX | -6.90% | $18.69B | +69.92% | 0.28% |
RDNT | -6.84% | $4.18B | -6.09% | 0.00% |
EVGO | -6.48% | $470.93M | +38.74% | 0.00% |
WRAP | -6.21% | $78.39M | -14.84% | 0.00% |
GEO | -6.17% | $3.48B | +64.31% | 0.00% |
EAT | -6.08% | $8.08B | +157.41% | 0.00% |
EME | -5.86% | $24.25B | +46.00% | 0.19% |
CABO | -5.63% | $766.56M | -61.04% | 6.49% |
LITB | -5.31% | $21.24M | -78.57% | 0.00% |
BTCT | -5.28% | $25.56M | +61.14% | 0.00% |
TLN | -5.24% | $12.57B | +132.28% | 0.00% |
Current Value
$48.981 Year Return
Current Value
$48.981 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CLSE | 0.40% | $190.30M | 1.44% |
COMT | 0.45% | $604.69M | 0.48% |
BILZ | -0.45% | $821.74M | 0.14% |
CONY | 0.81% | $1.39B | 1.22% |
BTAL | 1.02% | $296.22M | 1.43% |
TFLO | -1.19% | $6.82B | 0.15% |
BIL | -1.29% | $42.24B | 0.1356% |
STOT | 1.30% | $254.07M | 0.45% |
GSG | 1.63% | $959.40M | 0.75% |
TESL | 1.82% | $32.49M | 1.2% |
DBC | 1.86% | $1.23B | 0.87% |
DBMF | 1.93% | $1.17B | 0.85% |
KCCA | -2.08% | $109.43M | 0.87% |
CANE | -2.61% | $10.37M | 0.29% |
PDBC | 2.63% | $4.42B | 0.59% |
BOXX | 2.73% | $6.80B | 0.19% |
YBTC | 2.99% | $226.39M | 0.96% |
CORN | 3.19% | $44.67M | 0.2% |
WEAT | 3.28% | $117.15M | 0.28% |
BKCH | 3.28% | $181.41M | 0.5% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UUP | -26.66% | $201.63M | 0.77% |
USDU | -25.52% | $162.43M | 0.5% |
TAIL | -16.67% | $99.63M | 0.59% |
VIXY | -15.81% | $164.54M | 0.85% |
AGZD | -14.85% | $102.70M | 0.23% |
CLIP | -13.23% | $1.51B | 0.07% |
UGA | -10.11% | $72.33M | 0.97% |
USO | -6.97% | $1.13B | 0.6% |
CTA | -6.79% | $1.06B | 0.76% |
USL | -6.75% | $42.23M | 0.85% |
FTSD | -6.74% | $231.81M | 0.25% |
BNO | -6.69% | $103.79M | 1% |
OILK | -6.05% | $71.87M | 0.69% |
TPMN | -5.15% | $30.70M | 0.65% |
TBLL | -4.72% | $2.13B | 0.08% |
DBE | -4.54% | $52.20M | 0.77% |
IVOL | -4.23% | $347.03M | 1.02% |
DBO | -4.14% | $228.24M | 0.77% |
SHYM | -3.83% | $357.13M | 0.35% |
FMF | -3.60% | $158.70M | 0.95% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PPH | 59.99% | $610.46M | 0.36% |
IXJ | 54.66% | $3.75B | 0.41% |
HDEF | 53.90% | $2.03B | 0.09% |
SCHY | 53.54% | $1.18B | 0.08% |
GCOW | 52.76% | $2.32B | 0.6% |
EFAV | 52.02% | $5.50B | 0.2% |
EWL | 51.21% | $1.33B | 0.5% |
EWQ | 49.57% | $436.26M | 0.5% |
RSPH | 49.31% | $729.81M | 0.4% |
XLV | 48.92% | $34.28B | 0.09% |
FICS | 48.92% | $223.48M | 0.7% |
IYH | 48.92% | $2.73B | 0.39% |
IDLV | 48.89% | $400.39M | 0.25% |
BBH | 48.83% | $330.62M | 0.35% |
PID | 48.51% | $844.81M | 0.53% |
IEV | 48.36% | $2.29B | 0.61% |
IBB | 48.18% | $5.26B | 0.45% |
FHLC | 48.17% | $2.44B | 0.084% |
DWX | 48.13% | $478.17M | 0.45% |
BBEU | 48.11% | $4.57B | 0.09% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
WTTR | 0.01% | $940.11M | -14.56% | 2.99% |
ZVIA | 0.01% | $204.80M | +359.60% | 0.00% |
RCL | -0.06% | $88.56B | +109.87% | 0.75% |
PRIM | 0.09% | $4.43B | +67.21% | 0.36% |
KRNY | 0.11% | $441.08M | +15.96% | 6.40% |
GTE | 0.20% | $174.53M | -51.04% | 0.00% |
HAFC | -0.21% | $786.72M | +60.44% | 3.93% |
VTLE | 0.24% | $659.45M | -62.97% | 0.00% |
CRVO | 0.28% | $48.39M | -64.97% | 0.00% |
GATX | 0.29% | $5.66B | +19.53% | 1.50% |
REAL | -0.29% | $592.62M | +60.49% | 0.00% |
EW | -0.29% | $45.18B | -15.44% | 0.00% |
PRA | -0.29% | $1.17B | +89.68% | 0.00% |
AMR | 0.31% | $1.55B | -62.97% | 0.00% |
ZS | 0.33% | $48.16B | +55.91% | 0.00% |
HWKN | -0.36% | $3.14B | +66.06% | 0.48% |
WNC | -0.38% | $480.67M | -47.44% | 2.77% |
CARV | 0.39% | $8.88M | +26.23% | 0.00% |
NTGR | -0.40% | $837.31M | +97.35% | 0.00% |
ANGO | 0.42% | $381.30M | +65.32% | 0.00% |
Yahoo
European stocks are having a strong year. If the dollar continues to weaken, Europe may provide fertile hunting ground for dividend investors. Lower interest rates and proposals to increase defense spending have both contributed to U.S. stocks’ weak performance.
Yahoo
In Japan alone, around 4,000 individuals have a CIDP diagnosis.
Yahoo
Health care stocks were leaning lower premarket Tuesday with the iShares Biotechnology ETF (IBB) and
Yahoo
- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July 01, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise by Sanofi (Euronext: SAN FP). Sanofi has agreed to make st
Yahoo
Sanofi (ENXTPA:SAN) recently received orphan drug designation from Japan's Ministry of Health for riliprubart, aimed at treating chronic inflammatory demyelinating polyneuropathy. This underscores the company's focus on expanding treatment options for underserved patient populations. Despite this positive development, Sanofi's share price experienced little change in the past week. While the market indices such as the S&P 500 and Nasdaq achieved record highs, bolstered by easing geopolitical...
Yahoo
ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries, a treatment that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer1.